Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rheumatoid arthritis vaccine (IR 501) - Immune Response BioPharma

Drug Profile

Rheumatoid arthritis vaccine (IR 501) - Immune Response BioPharma

Alternative Names: AI 201; AI 204; AI 205; IR 201; IR 501; IR 703; RAVAX; Zyvac-RA

Latest Information Update: 10 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 18 May 2015 The vaccine is still in phase-III development for Rheumatoid arthritis in USA
  • 04 Feb 2014 Ravax™ is still in phase III development for Rheumatoid arthritis in USA
  • 25 Jun 2012 Phase-III clinical trials in Rheumatoid arthritis in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top